- Home
- VRCA vs ACRV Comparison
VRCA vs ACRV Comparison
Compare VRCA & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRCA
- ACRV
- Stock Information
- Founded
- VRCA 2013
- ACRV 2018
- Country
- VRCA United States
- ACRV United States
- Employees
- VRCA N/A
- ACRV N/A
- Industry
- VRCA Biotechnology: Pharmaceutical Preparations
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- VRCA Health Care
- ACRV Health Care
- Exchange
- VRCA Nasdaq
- ACRV Nasdaq
- Market Cap
- VRCA 58.7M
- ACRV 47.8M
- IPO Year
- VRCA 2018
- ACRV 2022
- Fundamental
- Price
- VRCA $4.82
- ACRV $1.54
- Analyst Decision
- VRCA Hold
- ACRV Buy
- Analyst Count
- VRCA 5
- ACRV 7
- Target Price
- VRCA $60.00
- ACRV $17.40
- AVG Volume (30 Days)
- VRCA 36.2K
- ACRV 3.4M
- Earning Date
- VRCA 11-03-2025
- ACRV 11-12-2025
- Dividend Yield
- VRCA N/A
- ACRV N/A
- EPS Growth
- VRCA N/A
- ACRV N/A
- EPS
- VRCA N/A
- ACRV N/A
- Revenue
- VRCA $14,704,000.00
- ACRV N/A
- Revenue This Year
- VRCA $264.34
- ACRV N/A
- Revenue Next Year
- VRCA $33.95
- ACRV $805.34
- P/E Ratio
- VRCA N/A
- ACRV N/A
- Revenue Growth
- VRCA 5.72
- ACRV N/A
- 52 Week Low
- VRCA $3.82
- ACRV $1.05
- 52 Week High
- VRCA $20.60
- ACRV $10.00
- Technical
- Relative Strength Index (RSI)
- VRCA 34.96
- ACRV 57.79
- Support Level
- VRCA $4.87
- ACRV $1.46
- Resistance Level
- VRCA $5.23
- ACRV $2.67
- Average True Range (ATR)
- VRCA 0.33
- ACRV 0.19
- MACD
- VRCA -0.02
- ACRV 0.01
- Stochastic Oscillator
- VRCA 11.03
- ACRV 17.88
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.